Sitemap - 2020 - The Trip Report by Beckley Waves
MDMA Saves Money; Can Psychedelics Save America? Science & Religion; Business Highlights
At-Home Treatment, Facilities Fees, and Consensus
Field Trip IPO; MindMed + NYU: News & Events
Botanical Pharmaceutical Co. Enters Psychedelic Space
Psychiatrists & Decriminalize Nature Oppose Oregon Ballot Measure
A New Dawn: Canadian Exodus & Alternative Capital
UC Berkeley's Psychedelic Science Center; COMPASS Pathways Road Show; News, Headlines, and Events
Psychoplastogens, Corporate Responsibility, and Shareholder Leverage
Non-Obvious Inflection Points towards Mainstreaming
Australia's Potential Rescheduling of MDMA & Psilocybin Could Effect...Everything
MindMed & ATAI's new Programs; Usona Restarts Trials; Considering Resilience
Psilocybin Cultivation and Delivery Trends
Prohibition, Bureaucracy and the limits of Decriminalization
Software Assisted, Psychedelic Assisted Psychotherapy: part 4/n
Revisiting Psychedelic Synthesis and Manufacturing
The State of the Emerging Psychedelic...Industry Part 2
The State of the Emerging Psychedelic...Industry Part 1
What Does TheraPsil's Victory Mean?
Follow up: Synthesis/Manufacturing Conundrum; news and headlines
Listening to Cannabis; MindMed Update; Manufacturing Questions and more
The Bureaucratic Burden on Psychedelic Science
Update on DMT Race & Decrim Efforts in Oakland/Canada
Has Mydecine/Neuropharm Discovered an Overlooked Accelerated Approval Pathway?
Psychedelics & Digital Phenotyping
AWAKN earns their Nutt; ATAI adds Kratom; a Legal primer for psychedelic co's; Champignon Wounded
Psychedelics meet Drug Delivery Innovation
Psychedelics-as-a-Service Revisited
Update from the Oregon Trail; Beckley to develop 5-MeO-DMT; COMPASS restarts Phase II; and more
Software Assisted Psychedelic Assisted Psychotherapy: Part 2/n
Software-Assisted Psychedelic-Assisted Psychotherapy: Part 1
Champignon: the jig is up or just a slap on the wrist?
Highlights and Analysis of ATAI's Fireside Chat
CORRECTION: Psychedelic Effect Size; Stock Index; DARPA funding; Canadian Circus Update
Psychedelic Effect Size; Stock Index; DARPA funding; Canadian Circus Update
MAPS; Numinus; Bill Clinton's Brother?
Crazy Idea: Pre-Approval Pragmatic Clinical Trials
The Trip Report Interview with Tania de Jong Executive Director of Mind Medicine Australia
Business & Science News Round up
Psychedelic Incubator; COMPASS Adds to SAB; Yeast: beer, bread & DMT;
George Floyd, the War on Drugs, and Psychedelics
Eleusis' New Patent & 'Health Solutions' Division
Psychedelics for Chronic Pain? The Problem and The Unmet Need
Numinus, Novamind, E.I. Foundation, Oregon Update
Cannabis Clinic ≠ Psychedelic Clinic
We're all going to die: TsuNumi Warning! & Champignon is an actual thing?
Off Label Use vs. Method of Use Patent
Psychedelic Premortem Categories
MAPS' Interim Analysis; Dr. Kim Kuypers named PI on LSD for ADHD
The Machine Elf will see you now: DMT in clinical Medicine
Canada, Hit the Brakes eh?; Meeting of the Five Families; Psychiatry Weighs in on Psychedelics
Healthy Growth; Usona & OrthoG's Turn to shine; Psychedelic Overton Window
Compass points to the bank; 2nd Generation Psychedelics; Mushroom Orchard
Tim Ferriss' Future Involvement in Psychedelics
ATAI Raises $24 Million; Manufacturing Considerations; CAAMTech Synthesizes 5-MeO-DALT
MAPS on Commercialization; MindMed: Bad Trip? No Problem; DecrimNatureDC Has the Data and a Plan
If MAPS Is a Public Benefit Corp, Should We All Be?
Psilly gets serious; Mindset is everything; Digital Season just getting started
Field Trip Discovery & Interview w/ CEO Ronan Levy
The Last Mile Problem Part 2: The Innovation and Delivery Divide
Correction: Numinus and the 'Picks and Shovels' of Psychedelic Medicine
Numinus and the 'Picks and Shovels' of Psychedelic Medicine
Trip Report Update; Virtual Conference; ATAI's Messaging, Tim Ferris Insight; and more
Strategy Decisions; Peyote issues; Perception phase I
Psychedelics as a Service: Oregon Update
MindMed's Ark; AYA Defense Fund; Set & Setting Study; COVID-19 Updates
A History Lesson; Brilliant Larry; Industry Report; Ketamine at home; and more.
Decriminalization clarity; Mindbloom's weird flex; and more
COVID-19 Comes for the Psychedelic Movement
A Survey of Decriminalization & Legalization Efforts
Sexual Assault; Decrim Oakland Update; Field Trip Launches
MindMed; Psychedelics + Virtual Reality; Growing Pains; PsyTech Postponed; Job Listings
MindMed Goes Public with 18-MC
Entheon Biomedical sics the Big Dogs on addiction; CaaMTech update and Headlines
Could a new diagnosis help psychedelics address opioid use disorder?
Psychedelic Media & Journalism Worth Following
Pro Subscribers Only: What do you want to know about iCAN &PsyTech?
The Trip Report Interview with Unlimited Sciences Co-Founder Del Jolly
Special Dispatch: Psychedelic Non-Profits Worth Supporting
Psychedelic Partnerships: Synthesis+4 Sigmatic; Revive+Red Light; YG+TLS; How to Spot a Lemon
Field Trip's Series A; Psychedelic Jobs; DC's First Step; Scientology be trippin'; and Other News
DemeRx has patents for days; Oh Ehave!; Natural Psilocybin solution; Psychedelic Exceptionalism;
MAPS Expands Access; Ibogaine pitched @ Davos; 'Psilocybin' Trademarked and more
Required Reading for Psychedelic Entrepreneurs and Investors: Part 1
DecrimCA update; Psychedelic Investor Seminar; COMPASS' Patent; Usona's anti-patent
Psychedelic Leaders' 2019 Reviews and 2020 Outlooks